癌症易感基因检测面板基因与乳腺癌之间的关联
该研究纳入65057例接受多基因癌症易感基因检测的乳腺癌患者,采用病例对照分析评估非BRCA1/BRCA2易感基因致病性变异与乳腺癌风险的关系。在41611例连续检测的白人乳腺癌患者中,21个面板基因致病性变异频率为10.2%;排除BRCA1、BRCA2及综合征相关基因后,ATM、BARD1、CHEK2、PALB2和RAD51D变异与乳腺癌风险升高相关。
要点
- 在41611例连续检测的白人乳腺癌患者中,21个面板基因致病性变异频率为10.2%。
- ATM、BARD1、CHEK2、PALB2和RAD51D变异与乳腺癌风险升高相关。
- BRIP1、RAD51C、MRE11A、RAD50、NBN、MLH1、PMS2和NF1变异未与乳腺癌风险升高相关。
核心结论
- 本研究确立多个面板基因作为高风险和中风险乳腺癌基因,并提供了符合临床遗传检测条件个体中这些基因致病性变异相关的乳腺癌风险估计。
研究设计与样本
- 研究人群为65057例接受癌症易感基因多基因面板检测的乳腺癌患者,采用乳腺癌患者与Exome Aggregation Consortium参考对照的病例对照分析。
- 女性受试者检测时间为2012年3月15日至2016年6月30日。
主要发现
- 65057例女性诊断时平均(SD)年龄为48.5(11.1)岁。
- 41611例连续检测的白人乳腺癌患者中,21个面板基因致病性变异频率估计为10.2%。
- 排除BRCA1、BRCA2及综合征乳腺癌基因(CDH1、PTEN和TP53)后,16个基因中5个基因的致病性变异与乳腺癌高风险或中度升高风险相关:ATM(OR,2.78;95%CI,2.22-3.62)、BARD1(OR,2.16;95%CI,1.31-3.63)、CHEK2(OR,1.48;95%CI,1.31-1.67)、PALB2(OR,7.46;95%CI,5.12-11.19)和RAD51D(OR,3.07;95%CI,1.21-7.88)。
- BRIP1和RAD51C卵巢癌风险基因、MRE11A、RAD50和NBN MRN复合体基因、MLH1和PMS2错配修复基因以及NF1的变异未与乳腺癌风险升高相关。
关键数值与推荐
- ATM变异与乳腺癌风险相关(OR,2.78;95%CI,2.22-3.62)。
- BARD1变异与乳腺癌风险相关(OR,2.16;95%CI,1.31-3.63)。
- CHEK2变异与乳腺癌风险相关(OR,1.48;95%CI,1.31-1.67)。
- PALB2变异与乳腺癌风险相关(OR,7.46;95%CI,5.12-11.19)。
- RAD51D变异与乳腺癌风险相关(OR,3.07;95%CI,1.21-7.88)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Germline pathogenic variants in BRCA1 and BRCA2 predispose to an increased lifetime risk of breast cancer. However, the relevance of germline variants in other genes from multigene hereditary cancer testing panels is not well defined. OBJECTIVE: To determine the risks of breast cancer associated with germline variants in cancer predisposition genes. DESIGN, SETTING, AND PARTICIPANTS: A study population of 65 057 patients with breast cancer receiving germline genetic testing of cancer predisposition genes with hereditary cancer multigene panels. Associations between pathogenic variants in non-BRCA1 and non-BRCA2 predisposition genes and breast cancer risk were estimated in a case-control analysis of patients with breast cancer and Exome Aggregation Consortium reference controls. The women underwent testing between March 15, 2012, and June 30, 2016. MAIN OUTCOMES AND MEASURES: Breast cancer risk conferred by pathogenic variants in non-BRCA1 and non-BRCA2 predisposition genes. RESULTS: The mean (SD) age at diagnosis for the 65 057 women included in the analysis was 48.5 (11.1) years. The frequency of pathogenic variants in 21 panel genes identified in 41 611 consecutively tested white women with breast cancer was estimated at 10.2%. After exclusion of BRCA1, BRCA2, and syndromic breast cancer genes (CDH1, PTEN, and TP53), observed pathogenic variants in 5 of 16 genes were associated with high or moderately increased risks of breast cancer: ATM (OR, 2.78; 95% CI, 2.22-3.62), BARD1 (OR, 2.16; 95% CI, 1.31-3.63), CHEK2 (OR, 1.48; 95% CI, 1.31-1.67), PALB2 (OR, 7.46; 95% CI, 5.12-11.19), and RAD51D (OR, 3.07; 95% CI, 1.21-7.88). Conversely, variants in the BRIP1 and RAD51C ovarian cancer risk genes; the MRE11A, RAD50, and NBN MRN complex genes; the MLH1 and PMS2 mismatch repair genes; and NF1 were not associated with increased risks of breast cancer. CONCLUSIONS AND RELEVANCE: This study establishes several panel genes as high- and moderate-risk breast cancer genes and provides estimates of breast cancer risk associated with pathogenic variants in these genes among individuals qualifying for clinical genetic testing.
引用
- Couch FJ, Shimelis H, Hu C, et al. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol. 2017. PMID: 28418444. doi:10.1001/jamaoncol.2017.0424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。